The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 19, 2008

Filed:

Apr. 26, 2004
Applicants:

Irun R. Cohen, Rehovot, IL;

Ofer Lider, Rehovot, IL;

Liora Cahalon, Givataim, IL;

Oded Shoseyov, Shimshon, IL;

Raanan Margalit, Rehovot, IL;

Inventors:

Irun R. Cohen, Rehovot, IL;

Ofer Lider, Rehovot, IL;

Liora Cahalon, Givataim, IL;

Oded Shoseyov, Shimshon, IL;

Raanan Margalit, Rehovot, IL;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/7016 (2006.01); A61K 31/727 (2006.01); C08B 37/10 (2006.01);
U.S. Cl.
CPC ...
Abstract

Substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, including compositions containing same and methods of using same, are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of Tumor Necrosis Factor Alpha (TNF-α) can be either inhibited or augmented selectively by administration to the host of effective amounts of substances or their compositions comprising specific oligosaccharides in substantially purified form. Thus, the present invention also relates to pharmaceutical compositions and their use for the prevention and/or treatment of pathological processes involving the induction of active cytokine secretion, such as TNF-α. The invention also relates to the initiation of a desirable immune system-related response by the host to the presence of activators, including pathogens. The substances and pharmaceutical compositions of the present invention may be daily, at very low effective doses, typically below 0.1 mg/kg human, or at intervals of up to about 5-8 days, preferably once a week.


Find Patent Forward Citations

Loading…